CPIX: Cumberland Pharmaceuticals Inc. - Summary | Jitta

Cumberland Pharmaceuticals Inc.

NASDAQ:CPIX

Price
$2.59
Loss Chance
44.6%
3.89JITTA SCORE
29.83%Under Jitta Line
Jitta Ranking
16 / 1,189
351 / 4,969
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (25)
Recent Business Performance (39)
Financial Strength (53)
Return to Shareholders (14)
Competitive Advantage (41)
Jitta Signs
Share RepurchaseEvery Year
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2021
Operating MarginDeclined
Recent Business PerformanceEarning decline 28.17% in the last year
CapExVery High
Key Stats
Jitta Score
Jitta Line
3.89
29.83%
1.94
293.46%
2.00
228.80%
Pharmaceuticals
6.67
35.50%
3.58
62.87%
4.51
75.73%
COMPANY DESCRIPTION
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.